Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 527

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 527
---
 2,352,670  
    $5.02  
    $- 

As
of December 31, 2024, options exercisable totaled 2,352,670. The Company recognized approximately $6.9 million in stock-based compensation
in 2024. There are approximately $2.2 million of unrecognized compensation cost
related to non-vested share-based compensation awards, which will be expensed through 2026.

Schedule of non vested share based compensation

     Exercise Price  
    Number
    Outstanding  
    Weighted
    Average Remaining Contractual Life (Years)  
    Weighted
    Average Exercise Price  
    Number
    Exercisable  
    Aggregate
    Intrinsic Price 
  
    $5.02  
     2,352,670  
     9.6  
    $5.02  
     1,046,335  
    $- 

Key
assumptions used to value stock options during the year ended December 31, 2024, are as follows:

 Schedule
of key assumptions used to value stock options

    Expected volatility 
     88.8%-90.4% 
  
    Risk-free interest rate 
     3.7%
  
    Exercise price 
    $5.02 
  
    Expected term (in years) 
     5.1
                                            to 5.62 years 
  
    Dividend yield 
     - 

    F-15

Telomir
                                            Pharmaceuticals, Inc.

notes
to the financial statements

DECEMBER
31, 2024 and  2023

Note
7 – Income Taxes

The
significant components of the Company’s net deferred tax assets are as follows as of December 31:

Schedule of net
deferred tax assets

    2024  
    2023 

    December
    31, 

    2024  
    2023 
  
    Deferred tax assets 

    Net operating
    loss carry-forward 
    $4,427,679  
    $288,379 
  
    Section 174 Qualified Research
    Expenditures 
     995,500  
     526,248 
  
    Stock Compensation 
     1,680,019  
     - 
  
    R&D Credit 
     51,278  
     -